# Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies

> **NCT05950308** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 61 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05950308
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-05
- **Primary completion:** 2022-07-14
- **Final completion:** 2022-07-14
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2023-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05950308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05950308, "Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying Therapies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05950308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*